Half-year report · Q2
4483.TEDINET S100UQ55
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.2bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥32.4bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥13.7bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥136.1bn | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥122.5bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥100.0bn | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥63.7bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥51.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥72.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.7bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥68.7bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥72.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥70.6bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥68.6bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥27.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥10.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥17m | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥24.9bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥341m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥33.51 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.76 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥42.2 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥33.18 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥69.95 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥40.53 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.9% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 57.6% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.6% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥379m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥649m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥649m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥116m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥19.2bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥19.2bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥5.0bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥338m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥50m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥133m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥38m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.0bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥13.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥89m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 769
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating profit loss IFRS | CurrentYTDDuration | 3250000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 29000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 3000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 17000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 86000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | 0 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 3615000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 3167000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-12 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第12期中（自 2024年４月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Company name in english cover page | FilingDateInstant | JMDC Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 兼 ＣＥＯ 野口 亮 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員 兼 ＣＦＯ 望月 智洋 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5733-5010 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 兼 ＣＦＯ 望月 智洋 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E35308 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 44830 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ＪＭＤＣ | |
| Filer name in english | FilingDateInstant | JMDC Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |